Emergency Repair of a Rupturing Ascending Aorta

Circulatory Arrest Time Above 30 Minutes Has Significantly Detrimental Effects on the Outcomes of Type A Aortic Dissection Repair

February 20, 2026 No Comments

This retrospective study of 109 patients undergoing emergent type A aortic dissection repair found that deep hypothermic circulatory arrest (DHCA) times exceeding 30 minutes were associated with significantly higher 30-day mortality, 12-month mortality, and postoperative stroke rates. Cerebral perfusion strategy did not alter stroke risk. The findings suggest that limiting circulatory arrest to under 30 minutes may improve survival and neurological outcomes.

Heart Transplantation Graft Survival Following Donation After Circulatory Death via Thoracoabdominal Normothermic Regional Perfusion

February 18, 2026 No Comments

This national cohort study analyzed adult heart transplants in the United States from 2020–2024 to compare graft survival among donation after circulatory death (DCD) using thoracoabdominal normothermic regional perfusion (TA-NRP), DCD with direct procurement and perfusion (DPP), and donation after brain death (DBD). Two-year graft and patient survival were comparable across groups, supporting broader use of TA-NRP in heart transplantation.

Preoperative Anemia Management and Its Economic Impact on Red Blood Cell Transfusion in Cardiac Surgery

Predictors and Economic Impact of Red Blood Cell Transfusion in Cardiac Surgery: A Simulated Cost Reduction Model for Preoperative Anemia Management

February 16, 2026 No Comments

This retrospective cohort study of 661 elective cardiac surgery patients identified preoperative anemia as the strongest independent predictor of red blood cell (RBC) transfusion (OR 3.67). Transfusion was associated with longer hospital stay, higher infection rates, prolonged ventilation, and a median cost increase of €2264 per patient. A simulation model estimated that eliminating preoperative anemia could prevent 47 transfusions and save €106 429 over 13 months.

Intravenous Lidocaine Infusion During Cardiopulmonary Bypass Cardiac Surgery

Evaluation of the Effect of Intravenous Lidocaine on the Systemic Inflammatory Response Associated With Cardiopulmonary Bypass in Valvular and/or Coronary Cardiac Surgery: Protocol for a Double-Blind Randomized Clinical Trial

February 16, 2026 No Comments

This single-center, double-blind randomized clinical trial (LEONARD Trial) evaluates whether intravenous lidocaine reduces systemic inflammation triggered by cardiopulmonary bypass in elective valvular and/or coronary cardiac surgery. Ninety patients will receive lidocaine or placebo, with IL-6 at 6 hours postoperatively as the primary endpoint. Secondary outcomes include inflammatory biomarkers, organ dysfunction, atrial fibrillation, ICU stay, opioid use, and 30-day mortality.

Optimising Protamine Dosing for Heparin Reversal After Cardiopulmonary Bypass: A Population Pharmacokinetic—Pharmacodynamic Study

February 15, 2026 No Comments

This prospective study of 68 cardiac surgery patients used pharmacometric modeling to determine optimal protamine dosing for reversing unfractionated heparin after cardiopulmonary bypass. Researchers found that a protamine-to-heparin ratio of 0.625:1 achieved complete reversal in 95% of patients, lower than the commonly used 1:1 ratio. The study also revealed that activated clotting time (ACT) unreliably reflects residual heparin, suggesting fixed low-ratio dosing may be a practical alternative requiring validation.

Zero-Balance Ultrafiltration Reduces Postoperative Delirium After Cardiac Surgery with Cardiopulmonary Bypass: A Randomized Controlled Trial

February 5, 2026 No Comments

This single-center randomized controlled trial evaluated whether adding zero-balance ultrafiltration (Z-BUF) to conventional ultrafiltration during cardiopulmonary bypass reduces postoperative delirium after cardiac surgery. Among 106 analyzed patients, Z-BUF significantly lowered delirium incidence within 7 postoperative days compared with conventional ultrafiltration alone, while no significant differences were observed in longer-term cognitive outcomes at 1 or 3 months.

Precision and Protection: Advanced Myocardial Preservation in Complex Cardiac Surgery

Custodial-HTK Cardioplegia in Conventional Cardiac Surgery: A Retrospective Analysis From UiTM

February 4, 2026 No Comments

This retrospective cohort study from a Malaysian tertiary cardiac center compares Custodial-HTK cardioplegia with conventional blood cardioplegia in elective on-pump cardiac surgery. Although Custodial-HTK was preferentially used in higher-risk and more complex cases with lower baseline LVEF and longer bypass times, postoperative outcomes, ICU stay, hospital stay, and 30-day mortality were comparable, supporting its safety and effectiveness.

Global Teamwork in Modern Myocardial Protection: Alternative Base Solutions for del Nido Cardioplegia

Alternative Base Solutions for del Nido Cardioplegia: Composition, Rationale, and Clinical Evidence

January 31, 2026 No Comments

This comprehensive review examines alternative crystalloid and whole-blood base solutions for del Nido cardioplegia, including normal saline, lactated Ringer’s, plain Ringer’s, Isolyte S, Ionosteril, and whole blood. Drawing on experimental models, randomized trials, and clinical studies, the article demonstrates that these alternatives provide myocardial protection and postoperative outcomes comparable to Plasma-Lyte A when appropriately buffered, supporting cost-effective and globally accessible cardiac surgery practice.

Active Myocardial Protection During Cardioplegic Arrest

Molecular and Cellular Mechanisms of Cardioplegic Protection in Surgical Myocardial Revascularization

January 31, 2026 No Comments

This comprehensive review explores how cardioplegia actively protects the myocardium during coronary artery bypass grafting. Beyond inducing cardiac arrest, cardioplegic solutions modulate calcium homeostasis, mitochondrial function, oxidative stress, inflammation, and apoptosis. By suppressing electromechanical activity and metabolic demand, cardioplegia prolongs ischemic tolerance and mitigates reperfusion injury, offering critical insights for optimizing myocardial protection strategies in modern cardiac surgery.

Comparison of 6% Hydroxyethyl Starch 130/0.4 vs 5% Albumin in Cardiopulmonary Bypass for Cardiac Surgery

January 31, 2026 No Comments

This meta-analysis evaluated 12 randomized trials (908 patients) comparing 6% hydroxyethyl starch (HES) 130/0.4 with 5% albumin during cardiopulmonary bypass in cardiac surgery. Most outcomes—including blood loss, transfusion rates, ICU stay, hospital stay, and mortality—were similar between groups. However, HES use was associated with a significantly higher risk of acute kidney injury, highlighting renal safety concerns despite comparable hemodynamic efficacy.